Belimumab in Early Systemic Lupus Erythematosus: A Propensity Score Matching Analysis

Overview

Journal Immun Inflamm Dis

Specialties Allergy & Immunology
Infectious Diseases

Date 2024 Aug 22

PMID 39172013

Authors

Chaofan Lu

Nan He

Lei Dou

Hongxia Yu

Mengtao Li

Xiaomei Leng

Xiaofeng Zeng

Affiliations

Soon will be listed here.

Abstract

Objective: This study aimed to evaluate the clinical efficacy of belimumab in patients with early systemic lupus erythematosus (SLE), defined as having a disease duration of less than 6 months.

Methods: We retrospectively identified patients with SLE in the early stage who received belimumab and standard of care (belimumab group) or standard of care alone (control group) since September 2020. Propensity score matching (PSM) was used to reduce potential bias. The primary endpoint was lupus low disease activity status (LLDAS) at weeks 12 and 24. The secondary endpoints were remission and the proportion of glucocorticoid dose tapering to 7.5 mg/day. The efficacy of belimumab in patients with lupus nephritis was also assessed.

Results: Out of 111 eligible patients, 16 patients in the belimumab group and 31 patients in the control group were identified by 1:2 PSM. At week 24, a significantly higher proportion of individuals achieved low disease activity state (LLDAS) in the belimumab group compared to the control group (56.3% vs. 19.4%, OR = 5.357, 95% CI = 1.417 to 20.260, p = 0.013). Furthermore, more patients in the belimumab group were reduced to low-dose glucocorticoid ( ≤ 7.5 mg/day) at week 24 (75.0% vs. 35.5%, OR = 5.182, 95%CI = 1.339 to 20.058, p = 0.017). Significant improvements in Patient Global Assessment scores were observed at Week 12 and 24 for those treated with belimumab compared to controls. In a subgroup analysis evaluating the efficacy of belimumab in patients with lupus nephritis, 42.9% of the seven individuals treated with belimumab achieved a complete renal response (CRR) by Week 24, and no instances of disease relapse were observed.

Conclusions: In SLE patients with a disease duration of less than 6 months, belimumab treatment can promote LLDAS achievement and reduce glucocorticoid dose, leading to a better prognosis. Introducing belimumab in the early stage of SLE may be a beneficial decision.

References

Kapsala N, Nikolopoulos D, Flouda S, Chavatza A, Tseronis D, Aggelakos M . From first symptoms to diagnosis of systemic lupus erythematosus: mapping the journey of patients in an observational study. Clin Exp Rheumatol. 2022; 41(1):74-81. DOI: 10.55563/clinexprheumatol/x3s9td. View

Kandane-Rathnayake R, Louthrenoo W, Hoi A, Luo S, Wu Y, Chen Y . 'Not at target': prevalence and consequences of inadequate disease control in systemic lupus erythematosus-a multinational observational cohort study. Arthritis Res Ther. 2022; 24(1):70. PMC: 8919535. DOI: 10.1186/s13075-022-02756-3. View

Oglesby A, Korves C, Laliberte F, Dennis G, Rao S, Suthoff E . Impact of early versus late systemic lupus erythematosus diagnosis on clinical and economic outcomes. Appl Health Econ Health Policy. 2014; 12(2):179-90. DOI: 10.1007/s40258-014-0085-x. View

Levy R, Gonzalez-Rivera T, Khamashta M, Fox N, Jones-Leone A, Rubin B . 10 Years of belimumab experience: What have we learnt?. Lupus. 2021; 30(11):1705-1721. PMC: 8564244. DOI: 10.1177/09612033211028653. View

van Vollenhoven R, Mosca M, Bertsias G, Isenberg D, Kuhn A, Lerstrom K . Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis. 2014; 73(6):958-67. DOI: 10.1136/annrheumdis-2013-205139. View

Gatto M, Saccon F, Zen M, Regola F, Fredi M, Andreoli L . Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life Setting. Arthritis Rheumatol. 2020; 72(8):1314-1324. DOI: 10.1002/art.41253. View

Navarra S, Guzman R, Gallacher A, Hall S, Levy R, Jimenez R . Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011; 377(9767):721-31. DOI: 10.1016/S0140-6736(10)61354-2. View

Mak A, Cheung M, Chiew H, Liu Y, Ho R . Global trend of survival and damage of systemic lupus erythematosus: meta-analysis and meta-regression of observational studies from the 1950s to 2000s. Semin Arthritis Rheum. 2012; 41(6):830-9. DOI: 10.1016/j.semarthrit.2011.11.002. View

Wallace D, Ginzler E, Merrill J, Furie R, Stohl W, Chatham W . Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019; 71(7):1125-1134. PMC: 6617785. DOI: 10.1002/art.40861. View

10.

Ruiz-Irastorza G, Bertsias G . Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs. Rheumatology (Oxford). 2020; 59(Suppl5):v69-v81. PMC: 7719039. DOI: 10.1093/rheumatology/keaa403. View

11.

Tan M, Xu J, Tan Y, Qu Z, Yu F, Zhao M . Efficacy and Safety of Belimumab in Lupus Nephritis Patients: A Real-World Observational Study in China. Kidney Dis (Basel). 2023; 9(3):218-228. PMC: 10368010. DOI: 10.1159/000529675. View

12.

van Vollenhoven R, Navarra S, Levy R, Thomas M, Heath A, Lustine T . Long-term safety and limited organ damage in patients with systemic lupus erythematosus treated with belimumab: a Phase III study extension. Rheumatology (Oxford). 2019; 59(2):281-291. PMC: 7571485. DOI: 10.1093/rheumatology/kez279. View

13.

Faurschou M, Starklint H, Halberg P, Jacobsen S . Prognostic factors in lupus nephritis: diagnostic and therapeutic delay increases the risk of terminal renal failure. J Rheumatol. 2006; 33(8):1563-9. View

14.

Al Sawah S, Zhang X, Zhu B, Magder L, Foster S, Iikuni N . Effect of corticosteroid use by dose on the risk of developing organ damage over time in systemic lupus erythematosus-the Hopkins Lupus Cohort. Lupus Sci Med. 2015; 2(1):e000066. PMC: 4378372. DOI: 10.1136/lupus-2014-000066. View

15.

Parra Sanchez A, Voskuyl A, van Vollenhoven R . Treat-to-target in systemic lupus erythematosus: advancing towards its implementation. Nat Rev Rheumatol. 2022; 18(3):146-157. DOI: 10.1038/s41584-021-00739-3. View

16.

Furie R, Rovin B, Houssiau F, Malvar A, Teng Y, Contreras G . Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis. N Engl J Med. 2020; 383(12):1117-1128. DOI: 10.1056/NEJMoa2001180. View

17.

Wu C, Gong B . Short-term clinical observations of belimumab in the treatment of recently diagnosed systemic lupus erythematosus. Immun Inflamm Dis. 2022; 10(11):e716. PMC: 9601783. DOI: 10.1002/iid3.716. View

18.

Emery P, Breedveld F, Hall S, Durez P, Chang D, Robertson D . Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet. 2008; 372(9636):375-82. DOI: 10.1016/S0140-6736(08)61000-4. View

19.

Danza A, Grana D, Soto E, Silveira G, Carlomagno A, Rebella M . Prednisone and long-term damage in systemic lupus erythematosus: Which is the threshold dose? A pilot study. Lupus. 2022; 31(7):880-884. DOI: 10.1177/09612033221093485. View

20.

Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis J . 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019; 78(6):736-745. DOI: 10.1136/annrheumdis-2019-215089. View